12/5
07:55 am
capr
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock [Yahoo! Finance]
12/5
06:35 am
capr
Capricor Therapeutics prices $150M stock offering [Seeking Alpha]
Low
Report
Capricor Therapeutics prices $150M stock offering [Seeking Alpha]
12/5
06:15 am
capr
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Low
Report
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
12/4
04:57 pm
capr
Capricor Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Capricor Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
12/4
04:01 pm
capr
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Medium
Report
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
12/4
12:01 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at Maxim Group.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at Maxim Group.
11/24
09:00 am
capr
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
High
Report
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
11/11
06:02 pm
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
Medium
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.
11/11
12:30 am
capr
Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
11/10
11:24 pm
capr
Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]
Medium
Report
Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel [Seeking Alpha]
11/10
04:04 pm
capr
Capricor Therapeutics, Inc. GAAP EPS of -$0.54 beats by $0.01 [Seeking Alpha]
Medium
Report
Capricor Therapeutics, Inc. GAAP EPS of -$0.54 beats by $0.01 [Seeking Alpha]
11/10
04:01 pm
capr
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/10
10:16 am
capr
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
Medium
Report
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
11/4
04:05 pm
capr
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
Low
Report
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
11/3
09:15 am
capr
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
Medium
Report
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
10/31
09:15 am
capr
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Low
Report
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
10/30
08:12 pm
capr
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last? [Yahoo! Finance]
Medium
Report
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last? [Yahoo! Finance]
10/28
02:20 pm
capr
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
10/8
02:16 pm
capr
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/6
08:00 am
capr
Rare Stock Picks In September 2025 - From 20 Discerning Analysts [Seeking Alpha]
Low
Report
Rare Stock Picks In September 2025 - From 20 Discerning Analysts [Seeking Alpha]
10/3
10:45 am
capr
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
Low
Report
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
9/29
09:09 am
capr
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway [Seeking Alpha]
Low
Report
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway [Seeking Alpha]
9/26
08:25 am
capr
Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
Medium
Report
Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
9/25
11:58 am
capr
Capricor Therapeutics, Inc. (CAPR) DMD Program Update Call (Transcript) [Seeking Alpha]
Low
Report
Capricor Therapeutics, Inc. (CAPR) DMD Program Update Call (Transcript) [Seeking Alpha]
9/25
11:52 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.